Aegros Announces Major Changes to its Management Team...
News
Aegros Secures Final Funding for Completion of its 125,000 Litre Haemafrac® Facility
Aegros Secures Final Funding for Completion of its...
Aegros Announces Share Purchase Plan Capital Raising Precusor to IPO
From the FoundersAs of next month it will...
Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune – TGA Application to follow
WATCH NOW – Aegros Founders and Chief Medical...
Australia’s leading blood fractionator announces a trio of strategic advisor appointments as it lays the groundwork for an IPO
Sydney, 23 November: AEGROS today cemented itself as...
Shareholder Announcement: Ernst & Young Appointed as Auditors
Aegros is pleased to announce the appointment of...
Historic Joint Venture to Build 1m Litre HaemaFrac® Facility in Singapore & Cambodia
Media Statement – Australia’s Leading Technology fractionator signs...
Promoting and Protecting Future Science and Scientists
Aegros recently had the pleasure of hosting two...
Aegros Appoints Father of India’s Blood Plasma Industry as Chief Executive Officer of Aegros Asia
The Aegros Group is pleased to announce that...
Aegros to present findings at ISTH 2023 Pt 2 – Hyperimmune neutralisation against Covid-19 variants
The International Society on Thrombosis and Homeostasis (ISTH)...
Aegros to present findings at ISTH 2023 Pt 1
The International Society on Thrombosis and Homeostasis (ISTH)...
